WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
5686072.pn. or 5593676.pn. or 5494899.pn.	6

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L19

Refine Search

Recall Text | Clear

Search History

DATE: Tuesday, August 27, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,DWPI; THES=ASSIGNEE; PLUR=YES; OP=OR		
L19	5686072.pn. or 5593676.pn. or 5494899.pn.	6	L19
L18	L16 and @RLAD<20000101	162	L18
	DB=USPT,PGPB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=OR		
L17	L16 and @RLAD<20000101	210	L17
L16	(((MSorEAE or sclerosis or autoimmun$).ab. or (MS or EAE or sclerosis or autoimmun$).clm.)) and ((B adj1 (cell or lymphocyte)) same (deplet$ or lyse or inactivat$ or eliminat$))	345	L16
L15	L14 and @RLAD<20000101	388	L15
L14	(((MSor EAE or sclerosis or autoimmun$).ab. or (MS or EAE or sclerosis or autoimmun$).clm.)) and ((B adj1 (cell or lymphocyte)) same (deplet$ or lyse or kill$ or inactivat$ or suppress or eliminat$))	710	L14
L13	(((MSorEAE or sclerosis or autoimmun$).ab. or (MS or EAE or sclerosis or autoimmun$).clm.)) and ((B adj1 (cell or lymphocyte)) same (deplet$ or lyse or kill$ or inactivat$ or suppress or eliminat$))	710	L13
L12	(((MSor EAE or sclerosis or autoimmun$).ab. or (MS or EAE or sclerosis or autoimmun$).clm.)) and (B adj1 (cell or lymphocyte)) same (deplet$ or lyse or kill$ or inactivat$ or suppress or eliminat$)	710	L12
L11	((MS or EAE or sclerosis or autoimmun$).ab. or (MS or EAE or sclerosis or autoimmun$).clm.) and (B adj1 (cell or lymphocyte)) same (deplet$ or lyse or kill$ or inactivat$ or suppress or eliminat$)	743	L11
L10	L5 and ((MS or EAE or sclerosis or autoimmun$).ab. or (MS or EAE or sclerosis or autoimmun$).clm.)	743	L10
L9	L5 same (MS or EAE or sclerosis or autoimmun$)	838	L9
L8	L5 same (MS or EAE or sclerosis or atuoimmun$)	563	L8
L7	L6 and (MS or EAE or sclerosis)	1677	L7
L6	L5 and autoimmun$	1767	L6
L5	(B adj1 (cell or lymphocyte)) same (deplet$ or lyse or kill$ or inactivat$ or suppress or eliminat$)	3622	L5
L4	Curd-John-g.in.	0	L4
L3	Nelson-M.-Bud.in.	0	L3
L2	Barbera-Guillem-emilo.in.	0	L2
L1	Hanna-nabil.in.	31	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 07:27:49 ON 27 AUG 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, PROMT' ENTERED AT 07:28:40 ON 27 AUG 2002

L1 3343 S CD22
L2 90220 S (MULTIPLE (1W) SCLEROSIS) OR EAE
L3 4886 S (B (1W) (CELL OR LYMPHOCYTE)) (5W) (DEPLET? OR ELIMINAT? OR L
L4 62 S L3 AND ((MULTIPLE (1W) SCLEROSIS) OR EAE OR MS)
L5 39 DUP REM L4 (23 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 07:44:34 ON 27 AUG 2002

L6 0 S L4 AND L1
L7 0 S L1 AND L3

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, PROMT' ENTERED AT 07:51:39 ON 27 AUG 2002

L8 1 S L6
L9 51 S L7
L10 1 S L1 AND L4
L11 51 S L1 AND L3
L12 26 DUP REM L11 (25 DUPLICATES REMOVED)
L13 1 S L12 AND L2
L14 16 S L1 AND L2
L15 12 DUP REM L14 (4 DUPLICATES REMOVED)

L15 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:220424 CAPLUS
DOCUMENT NUMBER: 136:246408
TITLE: Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination.
INVENTOR(S): Hanna, Nabil
PATENT ASSIGNEE(S): Idec Pharmaceuticals, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022212	A2	20020321	WO 2001-US29026	20010918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001091037	A5	20020326	AU 2001-91037	20010918
US 2002058029	A1	20020516	US 2001-954274	20010918

PRIORITY APPLN. INFO.:			
US 2000-257147P	P	20001222	
US 2000-233067P	P	20000918	
US 2000-233607P	P	20000918	
WO 2001-US29026	W	20010918	

L15 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:814347 CAPLUS
DOCUMENT NUMBER: 133:361915
TITLE: Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
INVENTOR(S): Curd, John G.; Kunkel, Lori A.; Grillo-Lopez, Antonio J.
PATENT ASSIGNEE(S): Genentech, Inc., USA; Idec Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067796	A1	20001116	WO 2000-US40018	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176981	A1	20020206	EP 2000-928991	20000504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011197	A	20020219	BR 2000-11197	20000504
NO 2001005417	A	20020107	NO 2001-5417	20011106

PRIORITY APPLN. INFO.: US 1999-133018P P 19990507
US 1999-139621P P 19990617
WO 2000-US40018 W 20000504
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 13 OF 39 MEDLINE DUPLICATE 3
ACCESSION NUMBER: 2000221272 MEDLINE
DOCUMENT NUMBER: 20221272 PubMed ID: 10756081
TITLE: B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bcl-2 expression.
AUTHOR: White C A; Nguyen K B; Pender M P
CORPORATE SOURCE: Neuroimmunology Research Unit, Department of Medicine, The University of Queensland, Clinical Sciences Building, Royal Brisbane Hospital, Brisbane, Queensland, 4029, Australia.
SOURCE: JOURNAL OF AUTOIMMUNITY, (2000 May) 14 (3) 195-204. Journal code: 8812164. ISSN: 0896-8411.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 20000706
Last Updated on STN: 20000706
Entered Medline: 20000626

AB The role and fate of B cells in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (**EAE**) are unknown. Using enzyme-linked immunospot assays we now show that B cells reactive to myelin basic protein (MBP) accumulate in the CNS of Lewis rats with acute **EAE** induced by immunization with MBP and adjuvants. We also report that **B cells** are **eliminated** from the CNS by apoptosis during spontaneous recovery from this disease. Apoptotic B cells were identified by flow cytometry of inflammatory cells extracted from the spinal cord and by histological sections of the spinal cord using light and electron microscopic immunocytochemistry. B cell apoptosis occurred preferentially in the CNS rather than in the peripheral lymphoid organs and was maximal just prior to the onset of spontaneous clinical recovery. Three colour flow cytometry indicated that B cells expressing CD95 (Fas) or CD95 ligand (CD95L) were highly vulnerable to apoptosis, whereas B cells expressing Bcl-2 were relatively protected from apoptosis. We propose that **B cells** are **eliminated** from the CNS by the interaction of CD95L and CD95 on the same B cell and that this contributes to the spontaneous resolution of CNS inflammation and clinical recovery in acute **EAE**.